FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid Leukaemia By Ogkologos - November 26, 2024 738 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ASC4FIRST study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Cetuximab No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies MOST POPULAR Study Finds the Cost of Treating Metastatic Breast Cancer Could More... August 3, 2021 Why I Work to Bridge the Gap Between People With Cancer... May 27, 2021 Pump Up the Volume: “Priming Agents” May Improve Cancer Liquid Biopsies February 22, 2024 Utility of Genomic Profiling Use for Targeted Therapy in a Phase... May 6, 2025 Load more HOT NEWS A Combination of Osimertinib Plus Pemetrexed and a Platinum-based Agent Significantly... New Research Looks for More Effective Breast Cancer Treatments for Black... People with Intellectual Disability at Increased Risk of Cancer Study Finds the Cost of Treating Metastatic Breast Cancer Could More...
